Abstract：
UNASSIGNED: To (1) measure surgical outcomes associated with stereotactic radiosurgery treatment of cerebellopontine angle meningiomas, and (2) determine if differences in radiation dosages or preoperative tumor volumes affect surgical outcomes.
UNASSIGNED: A systematic search was performed on the PubMed, Medline, Embase and Cochrane Library databases searching for patients under stereotactic radiosurgery for meningiomas of the cerebellopontine angle. After data extraction and Newcastle-Ottawa scale quality assessment, meta-analysis of the data was performed with Review Manager 3.4.5.
UNASSIGNED: In total, 6 studies including 406 patients were included. Postprocedure, patients had minimal cranial nerve complications while having an overall tumor control rate of 95.6%. Complications were minimal with facial nerve deficits occurring in 2.4%, sensation deficits of the trigeminal nerve in 4.0%, hearing loss in 5.9%, hydrocephalus in 2.0% and diplopia in 2.6% of all patients. Individuals with tumors extending into the internal auditory canal extension did not have significantly increases in hearing loss. There was a higher likelihood of tumor regression on postprocedure imaging in studies with a median prescription dose of >13 Gy (RR 1.27 [95% CI 1.04-1.56, p = 0.0225). There was no evidence of publication bias detected.
UNASSIGNED: Radiosurgery is an effective modality for offering excellent tumor control of CPA meningiomas while allowing for only minimal complications postprocedure. A higher prescription dose may achieve higher tumor regression at follow up. Future studies should aim at establishing and optimizing accurate dosimetric guidelines for this patient population.
UNASSIGNED: A systematic search was performed on the PubMed, Medline, Embase and Cochrane Library databases searching for patients under stereotactic radiosurgery for meningiomas of the cerebellopontine angle. After data extraction and Newcastle-Ottawa scale quality assessment, meta-analysis of the data was performed with Review Manager 3.4.5.
UNASSIGNED: In total, 6 studies including 406 patients were included. Postprocedure, patients had minimal cranial nerve complications while having an overall tumor control rate of 95.6%. Complications were minimal with facial nerve deficits occurring in 2.4%, sensation deficits of the trigeminal nerve in 4.0%, hearing loss in 5.9%, hydrocephalus in 2.0% and diplopia in 2.6% of all patients. Individuals with tumors extending into the internal auditory canal extension did not have significantly increases in hearing loss. There was a higher likelihood of tumor regression on postprocedure imaging in studies with a median prescription dose of >13 Gy (RR 1.27 [95% CI 1.04-1.56, p = 0.0225). There was no evidence of publication bias detected.
UNASSIGNED: Radiosurgery is an effective modality for offering excellent tumor control of CPA meningiomas while allowing for only minimal complications postprocedure. A higher prescription dose may achieve higher tumor regression at follow up. Future studies should aim at establishing and optimizing accurate dosimetric guidelines for this patient population.
摘要：
UNASSIGNED：（1）测量与立体定向放射外科治疗相关的手术结果桥脑角型脑膜瘤，（2）确定放射剂量或术前肿瘤体积的差异是否会影响手术结果。
UNASSIGNED：在PubMed上进行了系统搜索，Medline,Embase和Cochrane图书馆数据库在立体定向放射外科治疗桥脑角脑膜瘤中寻找患者。经过数据提取和纽卡斯尔-渥太华量表质量评估，使用ReviewManager3.4.5对数据进行荟萃分析。
未经批准：总共，纳入6项研究，包括406例患者。手术后,患者的颅神经并发症很少,但肿瘤总体控制率为95.6%.并发症最少，面神经缺损发生率为2.4％，三叉神经的感觉缺陷占4.0％，听力损失为5.9%，所有患者中有2.0%的脑积水和2.6%的复视。肿瘤延伸到内部耳道延伸的个体的听力损失没有显着增加。在中位处方剂量>13Gy的研究中，术后成像肿瘤消退的可能性更高（RR1.27[95％CI1.04-1.56，p=0.0225）。没有发现发表偏倚的证据。
UNASSIGNED：放射外科手术是一种有效的方式，可以为CPA脑膜瘤提供出色的肿瘤控制，同时仅允许最低限度的术后并发症。较高的处方剂量可以在随访时实现较高的肿瘤消退。未来的研究应旨在为该患者人群建立和优化准确的剂量学指南。
UNASSIGNED：在PubMed上进行了系统搜索，Medline,Embase和Cochrane图书馆数据库在立体定向放射外科治疗桥脑角脑膜瘤中寻找患者。经过数据提取和纽卡斯尔-渥太华量表质量评估，使用ReviewManager3.4.5对数据进行荟萃分析。
未经批准：总共，纳入6项研究，包括406例患者。手术后,患者的颅神经并发症很少,但肿瘤总体控制率为95.6%.并发症最少，面神经缺损发生率为2.4％，三叉神经的感觉缺陷占4.0％，听力损失为5.9%，所有患者中有2.0%的脑积水和2.6%的复视。肿瘤延伸到内部耳道延伸的个体的听力损失没有显着增加。在中位处方剂量>13Gy的研究中，术后成像肿瘤消退的可能性更高（RR1.27[95％CI1.04-1.56，p=0.0225）。没有发现发表偏倚的证据。
UNASSIGNED：放射外科手术是一种有效的方式，可以为CPA脑膜瘤提供出色的肿瘤控制，同时仅允许最低限度的术后并发症。较高的处方剂量可以在随访时实现较高的肿瘤消退。未来的研究应旨在为该患者人群建立和优化准确的剂量学指南。
